Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion?

A Shido1, S Ohmura, K Yamamoto

  • 1Department of Anesthesiology, Tatsunokuchi Houju Memorial Hospital, Tatsunokuchi-machi, Nomi-gun, Japan.

World Journal of Surgery
|April 29, 2000
PubMed
Summary

Continuous hyperthermic peritoneal perfusion (CHPP) does not cause peritoneal damage. Peritoneal damage is linked to anticancer drugs used in perfusion, not hyperthermia itself, in advanced gastric cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasound-guided lateral femoral cutaneous nerve block: comparison of two techniques.

Anaesthesia and intensive care·2011
Same author

IM droperidol as premedication attenuates intraoperative hypothermia.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2001
Same author

Peritoneal damage after continuous hyperthermic peritoneal perfusion.

Annals of the New York Academy of Sciences·1997
Same author

Bone marrow stromal cells attenuate mitoxantrone cytotoxicity against HL-60 leukemic cells.

Anti-cancer drugs·1992
Same author

[The resolution of D- and L-amino acids by reversed-phase high-performance liquid chromatography].

Seikagaku. The Journal of Japanese Biochemical Society·1992
Same author

[Antimutagenic substances in the Armeniacae semen and Persicae semen].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·1992

Area of Science:

  • Oncology
  • Surgical Oncology
  • Peritoneal Dialysis

Background:

  • Continuous hyperthermic peritoneal perfusion (CHPP) is used in treating advanced gastric cancer.
  • The mechanisms of peritoneal damage induced by CHPP require further investigation.

Purpose of the Study:

  • To investigate the mechanisms of peritoneal damage caused by CHPP.
  • To compare protein and fluid loss during and after CHPP versus continuous normothermic peritoneal perfusion (CNPP).

Main Methods:

  • Sixteen advanced gastric cancer patients underwent peritoneal perfusion therapy with cisplatin and mitomycin C.
  • Patients were divided into CHPP (n=9) and CNPP (n=7) groups, with perfusate temperatures of 42.0°C and 37.0°C, respectively.
  • Protein and fluid loss were measured during and after perfusion, and via abdominal drains post-surgery.

Related Experiment Videos

Main Results:

  • No significant differences in patient characteristics were observed between CHPP and CNPP groups, except for perfusate temperature.
  • Protein loss into the perfusate and fluid/protein loss through drains were not significantly different between the groups.
  • No significant differences in postoperative protein and fluid loss were found between the CHPP and CNPP groups over 3 days.

Conclusions:

  • Peritoneal damage associated with CHPP in advanced gastric cancer patients is not primarily caused by hyperthermia.
  • The peritoneal damage is attributed to the perfusion with saline solution containing anticancer drugs, rather than the elevated temperature.
  • This finding suggests that the chemotherapeutic agents are the main contributors to peritoneal injury during perfusion therapy.